• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

    1.234 -0.116 (-8.58%)
    Streaming Delayed Price Updated: 10:18 AM EDT, Sep 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 155,837
    Open 1.270
    Bid (Size) 1.210 (2,200)
    Ask (Size) 1.240 (1,800)
    Prev. Close 1.350
    Today's Range 1.200 - 1.275
    52wk Range 0.9500 - 52.50
    Shares Outstanding 15,859,280
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Friday's session: top gainers and losers ↗
    Via Chartmill
    Top movers analysis one hour before the close of the markets on 2026-08-27: top gainers and losers in today's session. ↗
    Via Chartmill

    Performance

    YTD
    -91.4%
    -91.4%
    1 Month
    +17.5%
    +17.5%
    3 Month
    -31.8%
    -31.8%
    6 Month
    -72.9%
    -72.9%
    1 Year
    -97.3%
    -97.3%

    More News

    Read More
    These stocks are the most active in today's session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    These stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    Thursday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    These stocks that are showing activity before the opening bell on Friday. ↗
    Via Chartmill
    Top movers analysis one hour before the close of the markets on 2026-06-11: top gainers and losers in today's session. ↗
    Via Chartmill
    These stocks are the most active in today's session ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    Which stocks are moving before the opening bell on Tuesday? ↗
    Via Chartmill
    News headline image
    Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
    From Propanc Biopharma, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Propanc Biopharma, Inc. - Common Stock publicly traded?
    Yes, Propanc Biopharma, Inc. - Common Stock is publicly traded.
    What exchange does Propanc Biopharma, Inc. - Common Stock trade on?
    Propanc Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Propanc Biopharma, Inc. - Common Stock?
    The ticker symbol for Propanc Biopharma, Inc. - Common Stock is PPCB on the Nasdaq Stock Market
    What is the current price of Propanc Biopharma, Inc. - Common Stock?
    The current price of Propanc Biopharma, Inc. - Common Stock is 1.234
    When was Propanc Biopharma, Inc. - Common Stock last traded?
    The last trade of Propanc Biopharma, Inc. - Common Stock was at 09/01/26 10:18 AM ET
    What is the market capitalization of Propanc Biopharma, Inc. - Common Stock?
    The market capitalization of Propanc Biopharma, Inc. - Common Stock is 19.57M
    How many shares of Propanc Biopharma, Inc. - Common Stock are outstanding?
    Propanc Biopharma, Inc. - Common Stock has 20M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.